The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
NEW YORK, Oct. 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
This report comprises defined and up to date development strategies for 531 antibody drugs in oncology within the portfolio of 196 companies world-wide, from Ceased to Marketed. The report extensively analyses their 255 identified drug targets, organized into 266 drug target strategies, and assesses them in 75 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the antibody drug pipeline in oncology and discern the level of competition in fine detail.
Major Findings from this report:
* The identified competitive landscape of antibody drugs in cancer is split between the 34% which have unique drug target strategies and the other part (66%) which have head-to-head target competing antibody drugs in 76 different clusters. The latter has a competing ratio which is two times higher than the comparable average of the antibody drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, ERBB2 and EGFR.
* Eight out of ten drug target strategies in Phase II development are new to antibody drugs in cancer and the greatest numbers of new target strategies are found in Preclinical (30%) and Phase II development (21%).
* The highest number of described target strategies among antibody drugs are found in Colorectal Cancer, Ovarian Cancer and Prostate Cancer. Antibody drugs are experiencing targeting competition in five out of every nine cancer indications described, and more so in Breast Cancer, Colorectal Cancer and non-Hodgkin's Lymphoma. Here, Ewing's Sarcoma makes out its own class by having five drugs but only towards one target strategy.
* The highest number of described drug target strategies of antibody drugs belongs to Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Immunomedics. However, when looking at the total number of drugs the order of the companies shifts into Hoffmann-La Roche, Immunomedics, Bristol-Myers Squibb, AstraZeneca and Eli Lilly.
* From an indication perspective it is Hoffmann-La Roche, Eli Lilly, Amgen, Pfizer and Bristol-Myers Squibb which take the lead in the widest coverage of cancer indications.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:
* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
* Supporting development of integrative molecule, pathway and disease area strategies
* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any antibody drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.
Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1469
Table 255: InNexus Biotechnology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1474
Table 256: Intracel's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1485
Table 257: ISA Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1489
Table 258: ISU ABXIS's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1493
Table 259: Johnson & Johnson's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1498
Table 260: Kaketsuken's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1505
Table 261: KaloBios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1508
Table 262: Kirin Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1511
Table 263: Kissei's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1516
Table 264: Kyowa Hakko Kirin's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1521
Table 265: Kyto Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1525
Table 266: LFB Biotechnologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1528
Table 267: LG Life Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1536
Table 268: MacroGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1541
Table 269: MAT Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1547
Table 270: Medarex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1552
Table 271: MediGene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1557
Table 272: MedImmune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1561
Table 273: Menarini's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1565
Table 274: Merck & Co's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1569
Table 275: Merck KGaA's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1574
Table 276: Merrimack's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1583
Table 277: Micromet's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1587
Table 278: Mitsubishi Tanabe Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1601
Table 279: Mycenax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1604
Table 280: Neovacs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1607
Table 281: Neuren's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1611
Table 282: NIH's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1614
Table 283: NKT Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1618
Table 284: Non-industrial Sources' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1621
Table 285: Northwest Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1627
Table 286: Novartis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1630
Table 287: OncoMed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1638
Table 288: Oncothyreon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1642
Table 289: Onyvax's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1646
Table 290: Oxford BioMedica's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1649
Table 291: Paladin Labs' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1652
Table 292: Panacea's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1658
Table 293: PanGenetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1663
Table 294: Patrys' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1667
Table 295: Pepscan Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1672
Table 296: Peregrine Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1676
Table 297: Perseus Proteomics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1681
Table 298: Pfizer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1684
Table 299: Philogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1699
Table 300: Pierre Fabre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1703
Table 301: Prima Biomed's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1711
Table 302: ProCell Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1714
Table 303: Prochon Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1717
Table 304: Progenics Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1721
Table 305: Ramot's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1724
Table 306: Recepta biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1727
Table 307: Receptor BioLogix's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1730
Table 308: Regeneron's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1734
Table 309: Sanofi-Aventis' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1741
Table 310: SBI Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1747
Table 311: Scancell's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1750
Table 312: Seattle Genetics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1753
Table 313: Shenogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1760
Table 314: Stainwei Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1763
Table 315: Sunol Molecular's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1766
Table 316: SuppreMol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1769
Table 317: Switch Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1772
Table 318: Symphogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1775
Table 319: Synageva BioPharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1780
Table 320: SynerGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1788
Table 321: Takeda's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1791
Table 322: Targa Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1794
Table 323: TeGenero's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1800
Table 324: Teva's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1803
Table 325: Therapure Biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1808
Table 326: ThromboGenics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1811
Table 327: Titan Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1816
Table 328: Tolerx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1821
Table 329: Tracon Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1825
Table 330: Transgene's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1828
Table 331: Trillium Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1831
Table 332: Trion Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1834
Table 333: UCB's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1841
Table 334: United Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1846
Table 335: Vaccinex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1849
Table 336: VasGene Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1857
Table 337: Viragen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1860
Table 338: Viventia Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1864
Table 339: Wakunaga's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1867
Table 340: Wilex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1871
Table 341: XBiotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1874
Table 342: Xencor's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1878
Table 343: Xerion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1893
Table 344: Xoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1898
Table 345: Y's Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1902
Table 346: YM BioSciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1906
Table 347: Zenotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1911Pharmaceuticals 1816
9.179 Tolerx 1821
9.180 Tracon Pharmaceuticals 1825
9.181 Transgene 1828
9.182 Trillium Therapeutics 1831
9.183 Trion Pharma 1834
9.184 UCB 1841
9.185 United Therapeutics 1846
9.186 Vaccinex 1849
9.187 VasGene Therapeutics 1857
9.188 Viragen 1860
9.189 Viventia Biotech 1864
9.190 Wakunaga 1867
9.191 Wilex 1871
9.192 XBiotech 1874
9.193 Xencor 1878
9.194 Xerion 1893
9.195 Xoma 1898
9.196 Y's Therapeutics 1902
9.197 YM BioSciences 1906
9.198 Zenotech 1911
10 Disclaimer 1917
11 Drug Index 1918
12 Company Index 1934
4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Oncology 383
Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Oncology - Large Clusters 385
Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Oncology - Smaller Clusters 386
Figure 4: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Larger Clusters 387
Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Oncology - Smaller Clusters 388
4.2 List of Tables
Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35
Table 3: Head to Head Target Competition among Antibody Drugs in Oncology 35
Table 4: Overview of Drug Target Strategy Themes 40
Table 5: Terminally Ceased Targets of Antibody Drugs in Oncology 41
Table 6: Official Gene Name to Target Profle 42
Table 7: Targets of Antibody Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 370
Table 8: Identity of Drug Targets with Available Biological Structures 376
Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Oncology 381
Table 10: Available Protein Expression Profiles of Antibody Drug Targets in Oncology 389
Table 11: Pathway Summary 394
Table 12: Drug Targets without any Identified Assigned Pathways 394
Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 397
Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 411
Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 427
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 431
Table 17: Top Competitive Target Strategies of Antibody Drugs in Oncology 432
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Antibody Drugs in Oncology 435
Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Oncology being Marketed or in Pre-registration 436
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Oncology 437
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Oncology 438
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Oncology 439
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Oncology 442
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Oncology 444
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Oncology 448
Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Oncology 449
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Oncology 454
Table 28: Target Strategies of Suspended and Terminated Antibody Drugs in Oncology 458
Table 29: Connecting Target Strategy with Its Profile Identification Number 463
Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Oncology 761
Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 770
Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 772
Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 773
Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 774
Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 775
Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 776
Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 777
Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 778
Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 779
Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 779
Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 780
Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 781
Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 782
Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 783
Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 784
Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 785
Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 786
Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 788
Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 790
Table 50: Target Strategy Development Profiles of Antibody Compounds for Cancer Diagnosis 791
Table 51: The Competition through Close Mechanistic Approximation between Cancer Diagnosis Compounds 792
Table 52: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer Fatigue 793
Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid 794
Table 54: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 795
Table 55: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 795
Table 56: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 796
Table 57: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 797
Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 799
Table 59: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 799
Table 60: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 800
Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 801
Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 802
Table 63: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 804
Table 64: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 806
Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing's Sarcoma 807
Table 66: The Competition through Close Mechanistic Approximation between Ewing's Sarcoma Drugs 807
Table 67: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 808
Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 809
Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 809
Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 810
Table 71: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 811
Table 72: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 812
Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 813
Table 74: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 813
Table 75: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 814
Table 76: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 814
Table 77: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 815
Table 78: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 816
Table 79: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 817
Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin's Lymphoma 818
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs 819
Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 820
Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 821
Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 822
Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 823
Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 824
Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 825
Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 826
Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 827
Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant Ascites 828
Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 829
Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 830
Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 831
Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 832
Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 833
Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 833
Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 834
Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 836
Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 837
Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 838
Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 839
Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 840
Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin's Lymphoma 841
Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 843
Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 845
Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 847
Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 848
Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 849
Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 850
Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 851
Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 851
Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 852
Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 854
Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 855
Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 857
Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 858
Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 859
Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 860
Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 861
Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 863
Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Anemia 864
Table 122: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Bone Marrow Injury (general) 865
Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Mucositis 866
Table 124: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Radio/chemotherapy-induced Thrombocytopenia 867
Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 868
Table 126: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 869
Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 870
Table 128: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 870
Table 129: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 871
Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 872
Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 873
Table 132: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 874
Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 875
Table 134: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 876
Table 135: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 878
Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 879
Table 137: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 879
Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 880
Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 881
Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 882
Table 141: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 883
Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 884
Table 143: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 884
Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Indication 885
Table 145: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs 889
Table 146: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 892
Table 147: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom`s hypergammaglobulinemia 893
Table 148: The Competition through Close Mechanistic Approximation between Waldenstrom`s hypergammaglobulinemia Drugs 893
Table 149: Competitive Summary by Investigator of Antibody Drug Development 894
Table 150: Summary Table of Corporate Changes in the Competitive Landscape of Antibody Drug Development in Oncology 898
Table 151: Example of a Competitive Fall-Out Table (Targeting ERBB2/Modified) 900
Table 152: A&G Pharmaceutical's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 902
Table 153: Abbott's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 905
Table 154: Abiogen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 912
Table 155: Ablynx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 919
Table 156: AC Immune's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 923
Table 157: Acceleron Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 926
Table 158: Access'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 929
Table 159: Actinium Pharmaceuticals'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 934
Table 160: Active Biotech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 938
Table 161: Adherex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 942
Table 162: Affibody's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 945
Table 163: Affimed Therapeutics'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 950
Table 164: Affitech's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 958
Table 165: AGY Therapeutics'Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 964
Table 166: Aida Pharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 967
Table 167: Alder Biopharmaceuticals' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 971
Table 168: Alethia Biotherapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 976
Table 169: Alexion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 979
Table 170: Alfacell's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 983
Table 171: Algeta's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 986
Table 172: ALSP's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 991
Table 173: Altor BioScience's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 996
Table 174: Amgen's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 999
Table 175: Amorfix Life Sciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1012
Table 176: Antisoma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1016
Table 177: Aphios' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1022
Table 178: Apricus Biosciences' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1026
Table 179: Arana Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1032
Table 180: Arca biopharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1035
Table 181: arGEN-X's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1039
Table 182: Astellas' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1043
Table 183: AstraZeneca's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1047
Table 184: Avaxia's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1062
Table 185: AVEO's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1066
Table 186: Bayer's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1074
Table 187: Berkeley Lab's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1078
Table 188: Biocon's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1081
Table 189: Biogen Idec's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1084
Table 190: BioInvent's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1097
Table 191: Biolex's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1101
Table 192: BioLineRx's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1105
Table 193: Biosceptre's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1108
Table 194: Biotecnol's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1111
Table 195: Biotest's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1117
Table 196: Boehringer Ingelheim's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1120
Table 197: Bristol-Myers Squibb's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1123
Table 198: BTG's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1141
Table 199: Cancer Innovations' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1145
Table 200: Cancer Research Technology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1148
Table 201: Celldex Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1162
Table 202: Celltrion's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1169
Table 203: Celtic Pharma's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1176
Table 204: Center of Molecular Immunology's Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1180
Table 205: CG Therapeutics' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1186
Table 206: Circadian Technologies' Included Antibody Drug Pipeline in Oncology and Competitive Fall-Out 1189
Table 207: CSL's Included Antibo
To order this report:
Pathology Industry: The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article